Plaintiff Firms Seek Lead Plaintiffs in Securities Suits Over Immutep’s TACTI‑004 Trial

Overview

• On June 29, multiple plaintiff-side law firms issued public notices inviting Immutep investors to join putative class actions and to apply for lead-plaintiff roles with a July 6, 2026 contact deadline.
• The complaints allege Immutep’s January 30, 2026 Form‑K falsely reported the TACTI‑004 study showed “strong operational progress” while the company allegedly knew the trial would not meet its primary efficacy endpoints.
• The filings invoke federal securities laws—Section 10(b), SEC Rule 10b‑5 and Section 20(a)—and define the proposed class as investors who bought Immutep securities from March 24, 2025 through March 12, 2026.
• Law firms are offering free consultations and are urging potential lead plaintiffs to act before the deadline, and they note the class has not been certified and the allegations remain unproven.
• If the court certifies a class and the claims succeed, investors may recover losses caused by the alleged concealment, underscoring that clinical trial disclosures can materially change a biotech company’s share value.